大阪公立大学大学院医学研究科　視覚病態学
ひかりをまもる -Save your vision-
私達は患者さんの視機能をより良く、より長期にわたって維持するためにあらゆる努力を続けています。
最新の機器と知識にもとづく最先端医療を提供しております。

業績 Achievement

Achievement

業績 Achievement

研究業績　2025年

  1. Mori Y, van Dijk EHC, Miyake M, Hosoda Y, den Hollander AI, Yzer S, Miki A, Chen LJ, Ahn J, Takahashi A, Morino K, Nakao SY, Hoyng CB, Ng DSC, Cen LP, Chen H, Ng TK, Pang CP, Joo K, Sato T, Sakata Y, Tajima A, Tabara Y; Nagahama Study Group; Park KH, Matsuda F, Yamashiro K, Honda S, Nagasaki M, Boon CJF, Tsujikawa A. Genome-wide association and multi-omics analyses provide insights into the disease mechanisms of central serous chorioretinopathy. Sci Rep. 2025;15(1):9158.
  2. Iida T, Gomi F, Yasukawa T, Yamashiro K, Honda S, Maruko I, Kataoka K; Japanese Retina and Vitreous Society Guidelines Committee for Neovascular Age-Related Macular Degeneration. Japanese clinical guidelines for neovascular age-related macular degeneration. Jpn J Ophthalmol. 2025;69(4):639-660.
  3. Yanagi Y, Mori R, Teo KYC, Park KH, Ngah NF, Chen SJ, Ruamviboonsuk P, Kondo N, Lee WK, Rajagopalan R, Obata R, Wong IYH, Chee C, Terasaki H, Sekiryu T, Chen SC, Lai TYY, Cheung G, Honda S. Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis. Jpn J Ophthalmol. 2025;69(6):894-901.
  4. Honda S, Maruyama-Inoue M, Otsuji T, Kyo A, Kobayashi Y, Yamamoto Y, Gomi F. Efficacy and safety of brolucizumab every 6 weeks induction therapy for neovascular age-related macular degeneration. Sci Rep. 2025;15(1):5705.
  5. Honda S. The Past, Present, and Future Perspective of Photodynamic Therapy for Age-Related Macular Degeneration. J Clin Med. 2025;14(4):1240.
  6. Tien LV, Yamamoto M, Tagami M, Misawa N, Honda S. Immunohistochemical expression of Fibrillin-1 in idiopathic epiretinal membranes. Graefes Arch Clin Exp Ophthalmol. 2025;263(2):415-424.
  7. Tien LV, Yamamoto M, Tagami M, Honda S. Different distribution and density of myofibroblasts in idiopathic epiretinal membrane and epiretinal membrane in proliferative diabetic retinopathy. Sci Rep. 2025;15(1):22767.
  8. Haruna Y, Tagami M, Kinari G, Sakai A, Honda S. Correlation Between Postoperative Vitreous Hemorrhage and Preoperative Evaluation of Optical Coherence Tomography Angiography in Proliferative Diabetic Retinopathy Surgery. J Ophthalmol. 2025;2025:7839246.
  9. Haruna Y, Tagami M, Tomita M, Sakai A, Misawa N, Asano K, Murai Y, Yoshikawa A, Azumi A, Honda S. Correlation Between Changes in Extraocular Muscles and Intraocular Pressure Following Anti-Inflammatory Therapy in Active Thyroid Eye Disease. J Clin Med. 2025;14(5):1480.
  10. Kinari G, Tagami M, Tomita M, Misawa N, Sakai A, Haruna Y, Shimono T, Honda S. A Case of Branch Retinal Artery Occlusion With Concomitant Intraocular and Extraocular Toxoplasmosis Lesions in a Japanese Man. Case Rep Ophthalmol Med. 2025;2025:6654053.
  11. Yamamoto M, Hirayama K, Kyo A, Kinari G, Kojima Y, Kohno T, Honda S. Immediate and Short-Term Intraocular Pressure Changes Following Intravitreal Injection and Associated Factors. J Clin Med. 2025;14(14):4821.
  12. Tagami M, Honda S. Applications of New Generation Sequencing (NGS) in Ocular Oncology. Int Ophthalmol Clin. 2025;65(4):1-4.
  13. Tagami M, Isayama K, Nishio M, Yoshikawa A, Misawa N, Sakai A, Haruna Y, Tomita M, Mizukami Y, Azumi A, Honda S. Gene expression cluster differences and molecular correlation with the STING pathway in orbital MALT lymphoma and orbital IgG4-related eye disease. Discov Oncol. 2025;16(1):1466.

研究業績　2024年

  1. Ueno Y, Haruna Y, Tomita M, et al. The effectiveness of pattern scanning laser trabeculoplasty as an additional treatment for the patients of open-angle glaucoma receiving full ocular hypotensive medications. J Clin Med. 2024;13(11):3266.
  2. Nihei A, Yamamoto M, Hirayama K, et al. The impact of removing the epiretinal membrane and inner limiting membrane for sustained subretinal fluid by macular neovascularization refractory to anti-VEGF therapy. Am J Ophthalmol Case Rep. 2024:35:102078.
  3. Tagami M, Nishio M, Yoshikawa A, Misawa N, Sakai A, Haruna Y, Tomita M, Azumi A, Honda S. Artificial intelligence-based differential diagnosis of orbital MALT lymphoma and IgG4 related ophthalmic disease using hematoxylin-eosin images. Graefes Arch Clin Exp Ophthalmol. 2024;262(10):3355-3366.
  4. Honda S, Misawa N, Sato Y, Oikawa D, Tokunaga F. The hypothetical molecular mechanism of the ethnic variations in the manifestation of age-related macular degeneration; focuses on the functions of the most significant susceptibility genes. Graefes Arch Clin Exp Ophthalmol. 2024;262(9):2799-2811.
  5. Koizumi H, Gomi F, Tsujikawa A, Honda S, Mori R, Ochi H, Iwasaki K, Okada AA; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial. Graefes Arch Clin Exp Ophthalmol. 2024;262(8):2439-2448.
  6. Tagami M, Kasashima H, Kakehashi A, Yoshikawa A, Nishio M, Misawa N, Sakai A, Wanibuchi H, Yashiro M, Azumi A, Honda S. Stromal area differences with epithelial-mesenchymal transition gene changes in conjunctival and orbital mucosa-associated lymphoid tissue lymphoma. Front Oncol. 2024;14:1277749.
  7. Teo KYC, Park KH, Ngah NF, Chen SJ, Ruamviboonsuk P, Mori R, Kondo N, Lee WK, Rajagopalan R, Obata R, Wong IYH, Chee C, Terasaki H, Sekiryu T, Chen SC, Yanagi Y, Honda S, Lai TYY, Cheung CMG. Six-Year Outcomes in Subjects with Polypoidal Choroidal Vasculopathy in the EVEREST II Study. Ophthalmol Ther. 2024;13(4):935-954.
  8. Kyo A, Yamamoto M, Kohno T, Haruna Y, Honda S. Symptoms of Isolated Optic Neuropathy in a Patient with Systemic, Brain, and Meningeal Metastases from Breast Cancer: A Case Report. Case Rep Ophthalmol. 2024;15(1):71-77.
  9. Inoda S, Takahashi H, Maruyama-Inoue M, Ikeda S, Sekiryu T, Itagaki K, Matsumoto H, Mukai R, Nagai Y, Ohnaka M, Kusuhara S, Miki A, Okada AA, Nakayama M, Nishiguchi KM, Takeuchi J, Mori R, Tanaka K, Honda S, Kohno T, Koizumi H, Miyara Y, Inoue Y, Takana H, Iida T, Maruko I, Hayashi A, Ueda-Consolvo T, Yanagi Y. Incidence and risk factors of intraocular inflammation after brolucizumab treatment in japan: A Multicenter Age-Related Macular Degeneration Study. Retina. 2024;44(4):714-722.
  10. Hirayama K, Yamamoto M, Honda S, Kyo A, Misawa N, Kohno T. Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness. J Clin Med. 2024;13(15):4375.
  11. Tomita M, Yamamoto M, Hirayama K, Kyo A, Misawa N, Kinari G, Kohno T, Honda S. One-Year Outcome of Intravitreal Injection of Ranibizumab Biosimilar for Myopic Choroidal Neovascularization in Japanese Patients. J Clin Med. 2024;13(16):4641.
  12. Sakai A, Tagami M, Misawa N, Haruna Y, Tomita M, Honda S. Serum PD-1 regulation and PD-1 expression of CD4+Foxp3+ regulatory T cells in patients in thyroid eye disease associated with immunosuppression treatment. Front Ophthalmol (Lausanne). 2024;4:1491053.
  13. Tomita M, Tagami M, Misawa N, Sakai A, Haruna Y, Honda S. Relationship between vitreous interleukin-6 levels and vitreous particles findings on widefield optical coherence tomography in posterior uveitis. PLoS One. 2024;19(1):e0297201.

研究業績　2023年

  1. Misawa N, Honda S. Increased sodium fluorescein transport by corticosteroids is inhibited by a LAT-1 specific inhibitor in retinal pigment epithelial cells in vitro. Sci Rep. 2023 Dec 27;13(1):22981. doi: 10.1038/s41598-023-50196-z.
  2. Tagami M, Nishio M, Katsuyama-Yoshikawa A, Misawa N, Sakai A, Haruna Y, Azumi A, Honda S. Machine Learning Model with Texture Analysis for Automatic Classification of Histopathological Images of Ocular Adnexal Mucosa-associated Lymphoid Tissue Lymphoma of Two Different Origins. Curr Eye Res. 2023 Aug 23:1-8. doi: 10.1080/02713683.2023.2246696.
  3. Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, Ohsawa S, Okada AA; TENAYA and LUCERNE Investigators. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Jpn J Ophthalmol. 2023 May;67(3):301-310. doi: 10.1007/s10384-023-00985-w.
  4. Yamada-Okahara N, Kyo A, Hirayama K, Yamamoto M, Kohno T, Honda S. Practical treatment options for persistent central serous chorioretinopathy and early visual and anatomical outcomes. Jpn J Ophthalmol. 2023 May;67(3):295-300. doi: 10.1007/s10384-023-00978-9.
  5. Akiyama M, Miyake M, Momozawa Y, Arakawa S, Maruyama-Inoue M, Endo M, Iwasaki Y, Ishigaki K, Matoba N, Okada Y, Yasuda M, Oshima Y, Yoshida S, Nakao SY, Morino K, Mori Y, Kido A, Kato A, Yasukawa T, Obata R, Nagai Y, Takahashi K, Fujisawa K, Miki A, Nakamura M, Honda S, Ushida H, Yasuma T, Nishiguchi KM, Mori R, Tanaka K, Wakatsuki Y, Yamashiro K, Kadonosono K, Terao C, Ishibashi T, Tsujikawa A, Sonoda KH, Kubo M, Kamatani Y. Genome-Wide Association Study of Age-Related Macular Degeneration Reveals 2 New Loci Implying Shared Genetic Components with Central Serous Chorioretinopathy. Ophthalmology. 2023 Apr;130(4):361-372. doi: 10.1016/j.ophtha.2022.10.034.
  6. Yamamoto M, Miura Y, Hirayama K, Kyo A, Kohno T, Theisen-Kunde D, Brinkmann R, Honda S. Comparative Treatment Study on Macular Edema Secondary to Branch Retinal Vein Occlusion by Intravitreal Ranibizumab with and without Selective Retina Therapy. Life (Basel). 2023 Mar 13;13(3):769. doi: 10.3390/life13030769.
  7. Tomita M, Tagami M, Misawa N, Sakai A, Haruna Y, Honda S. En-face widefield optical coherence tomography angiography for understanding vascular networks changes in two cases of acute retinal necrosis. J Ophthalmic Inflamm Infect. 2023 Mar 7;13(1):9. doi: 10.1186/s12348-023-00331-8.
  8. Sakai A, Tagami M, Katsuyama-Yoshikawa A, Misawa N, Haruna Y, Azumi A, Honda S. Relationship between Vitreous IL-6 Levels, Gender Differences and C-Reactive Protein (CRP) in a Blood Sample of Posterior Uveitis. J Clin Med. 2023 Feb 21;12(5):1720. doi: 10.3390/jcm12051720.
  9. Misawa N, Tagami M, Sakai A, Haruna Y, Honda S. Relationship between ultra-widefield optical coherence tomography and ophthalmoscopy for detecting posterior inflammation in posterior uveitis and panuveitis. PLoS One. 2023 Feb 10;18(2):e0281714. doi: 10.1371/journal.pone.0281714.

研究業績　2022年

  1. Honda S, Kohno T, Yamamoto M, Hirayama K, Kyo A, Hirabayashi M, Honda S. Early anatomical changes and association with photodynamic therapy induced acute exudative maculopathy in patients with macular diseases. Sci Rep. 2022;12(1):9105.
  2. Kyo A, Yamamoto M, Honda S. A case of angioid streaks that produced choroidal neovascularization after the onset of unilateral acute retinopathy in pseudoxanthoma elasticum. Am J Ophthalmol Case Rep. 2022;27:101591.
  3. Kyo A, Yamamoto M, Nagatomi Y, Kohno T, Honda S. Fundus white spots associated with graft-versus-host disease in the remission phase of acute myeloid leukemia. Am J Ophthalmol Case Rep. 2022;27:101609.
  4. Ueno Y, Honda S. A Case of Traumatic Medial Longitudinal Fasciculus Syndrome Whose Causal Lesion Was Detected by Thin-Section MRI with Susceptibility-Weighted Imaging. Case Rep Ophthalmol. 2022;13(2):368-373.
  5. Ishiguro N, Hayashi T, Yamawaki Y, Mizobuchi K, Yasukawa T, Honda S, Nakano T. Multimodal Imaging of Subfoveal Pachydrusen Containing a Blood Flow Signal. Case Rep Ophthalmol Med. 2022;2022:5680913.
  6. Tagami M, Kakehashi A, Katsuyama-Yoshikawa A, Misawa N, Sakai A, Wanibuchi H, Azumi A, Honda S. FOXP3 and CXCR4-positive regulatory T cells in the tumor stroma as indicators of tumor immunity in the conjunctival squamous cell carcinoma microenvironment. PLoS One. 2022;17(3):e0263895.
  7. Tagami M, Misawa N, Noma-Ishikura S, Honda S, Kase S, Honda S. Epidermal growth factor receptor expression in a case of focal nodular gliosis of the retina. Retin Cases Brief Rep. 2022;16(3):375-378.
  8. Mori Y, Miyake M, Hosoda Y, Miki A, Takahashi A, Muraoka Y, Miyata M, Sato T, Tamura H, Ooto S, Yamada R, Yamashiro K, Nakamura M, Tajima A, Nagasaki M, Honda S, Tsujikawa A. Genome-wide Survival Analysis for Macular Neovascularization Development in Central Serous Chorioretinopathy Revealed Shared Genetic Susceptibility with Polypoidal Choroidal Vasculopathy. Ophthalmology. 2022:S0161-6420(22)00306-2.
  9. Sakai A, Tagami M, Misawa N, Yamamoto M, Kohno T, Honda S. Safety and efficacy of 27-gauge transconjunctival vitrectomy for the diagnosis of posterior uveitis or pan uveitis of unknown origin. BMC Ophthalmol. 2022;22(1):178.
  10. Kojima Y, Misawa N, Yamamoto T, Honda S. Intraoperative alteration in the vital signs of diabetic patients during cataract surgery with local anesthesia. PLoS One. 2022;17(3):e0265135.
  11. Tagami M, Honda S, Azumi A. Insights into Current Management Strategies for Dysthyroid Optic Neuropathy: A Review. Clin Ophthalmol. 2022;16:841-850.

研究業績　2021年

  1. Honda S, Yanagi Y, Koizumi H, Chen Y, Tanaka S, Arimoto M, Imai K. Impact of neovascular age-related macular degeneration: burden of patients receiving therapies in Japan. Sci Rep. 2021;11(1):13152.
  2. Kyo A, Yamamoto M, Hirayama K, Kohno T, Theisen-Kunde D, Brinkmann R, Miura Y, Honda S. Factors affecting resolution of subretinal fluid after selective retina therapy for central serous chorioretinopathy. Sci Rep. 2021;11(1):8973.
  3. Hirayama K, Yamamoto M, Kohno T, Kyo A, Theisen-Kunde D, Brinkmann R, Miura Y, Honda S. Selective retina therapy (SRT) for macular serous retinal detachment associated with tilted disc syndrome. Graefes Arch Clin Exp Ophthalmol. 2021;259(2):387-393.
  4. Tagami M, Misawa N, Sakai A, Honda S. Two Cases of Extremely High-IL-6 Pan-uveitis with Subretinal Exudation and Cell Migration. Ocul Immunol Inflamm. 2021 May 12:1-5.
  5. Misawa N, Tagami M, Sakai A, Kohno T, Honda S. Visual outcomes and choroidal thickness associated with human leukocyte antigen DRB1*04 in unclassifiable uveitis in Japanese patients. BMC Ophthalmol. 2021;21(1):457.
  6. Tagami M, Kakehashi A, Sakai A, Misawa N, Katsuyama-Yoshikawa A, Wanibuchi H, Azumi A, Honda S. Expression of thrombospondin-1 in conjunctival squamous cell carcinoma is correlated to the Ki67 index and associated with progression-free survival. Graefes Arch Clin Exp Ophthalmol. 2021;259(10):3127-3136.
  7. 山本 学, 安川 力, 高橋 寛二.　抗VEGF治療セミナー　光干渉断層血管撮影の加齢黄斑変性における活用法　あたらしい眼科2021;38(12):1483-1484.
  8. 本田 茂.【黄斑の最新レーザー診断、検査、治療】眼科における光線力学的療法(PDT)の歴史と現状 日本レーザー医学会誌2021;42(2):78-88.
  9. 平山 公美子, 山本 学.【黄斑の最新レーザー診断、検査、治療】網膜疾患に対する選択的網膜色素上皮レーザー治療(Selective Retina Therapy、SRT)の臨床研究 日本レーザー医学会誌2021;42(2):89-95.
  10. 本田 聡, 山本 学, 中尾 拓貴, 本田 茂.　リネゾリドによる視神経症が疑われた多剤耐性肺結核の1例　臨床眼科2021;75(4):508-513.

研究業績　2020年

  1. Tagami M, Honda S, Azumi A. Preoperative clinical factors and visual outcomes following orbital decompression with dysthyroid optic neuropathy. BMC Ophthalmol. 2020;20:30.
  2. Tagami M, Misawa N, Noma-Ishikura S, Honda S, Kase S, Honda S. Epidermal Growth factor receptor expression in a case of focal nodular gliosis of the Retina. Retin Cases Brief Rep. 2020 Feb 13. doi: 10.1097/ICB.0000000000000987. Epub ahead of print. PMID: 32058355.
  3. Sakai A, Tagami M, Kakehashi A, Katsuyama-Yoshikawa A, Misawa N, Wanibuchi H, Azumi A, Honda S. Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment. PLoS One. 2020;15:e0238120.
  4. Misawa N, Tagami M, Sakai A, Kohno T, Honda S. Rapid regression of scleral melting associated with tumor necrosis factor-α in a case of surgically induced necrotizing scleritis. Case Rep Ophthalmol. 2020;11:418-422.
  5. Yamamoto M, Miura Y, Kyo A, Hirayama K, Kohno T, Theisen-Kunde D, Brinkmann R, Honda S. Selective retina therapy for subretinal fluid associated with choroidal nevus. Am J Ophthalmol Case Rep. 2020;19:100794.
  6. Yamamoto M, Miura Y, Hirayama K, Kohno T, Kabata D, Theisen-Kunde D, Brinkmann R, Honda S. Predictive factors of outcome of selective retina therapy for diabetic macular edema. Int Ophthalmol. 2020;40:1221-1232.
  7. Tamachi T, Kohno T, Yamamoto M, Hirayama K, Kyo A, Ueda N, Hirabayashi M, Shiraki K, Honda S. One-year results of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmol Ther. 2020;9:1069-1082.
  8. Nishimura S, Sugimoto A, Kushiyama S, Togano S, Kuroda K, Yamamoto Y, Yamauchi M, Sumi T, Kaneda H, Kawaguchi T, Kato M, Tagami M, Oebisu N, Hoshi M, Kimura K, Kubo S, Muguruma K, Takashima T, Ohira M, Yashiro M. Clinical benefit for clinical sequencing using cancer panel testing. PLoS One. 2021;16:e0247090.
  9. Hayashida M, Miki A, Nakai S, Matsumiya W, Imai H, Kusuhara S, Honda S, Nakamura M. Genetic factors associated with treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy. Mol Vis. 2020;26:505-509.
  10. Hayashida M, Miki A, Honda S, Nakamura M. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Photodiagnosis Photodyn Ther. 2020;31:101955.
  11. 田町 知子, 河野 剛也, 山本 学, 平山 公美子, 居 明香, 平林 倫子, 本田 茂. 初回と2回目の光線力学的療法後に異なる早期反応を示したポリープ状脈絡膜血管症の一例. 眼科臨床紀要2020;1:802-806.
  12. 西野 智之, 山本 学, 河野 剛也, 本田 茂. 残存水晶体嚢が再発性硝子体出血の原因と思われた1例. あたらしい眼科2020;37:89-93.
  13. 本田 茂.【眼科救急疾患2020】網膜硝子体　原因不明の硝子体出血. 眼科 2020;62:1277-1281.
  14. 平山 公美子.【すべて見せます!患者説明・同意書マニュアル】AMD　蛍光眼底造影検査. 臨床眼科2020;74:267-269.
  15. 山本 学. 内科医・眼科医連携のピットフォール　網膜症以外に注意しなければいけない眼科疾患. 糖尿病合併症2020;34:38-41.
  16. 本田 茂. 知っておくと得をするRetina百科(第16回)　光線力学療法(PDT)の現状と使い方. Retina Medicine 2020;9:90-92.

研究業績　2019年

  1. Hosoda Y, Miyake M, Schellevis RL, Boon CJF, Hoyng CB, Miki A, Meguro A, Sakurada Y, Yoneyama S, Takasago Y, Hata M, Muraoka Y, Nakanishi H, Oishi A, Ooto S, Tamura H, Uji A, Miyata M, Takahashi A, Ueda-Arakawa N, Tajima A, Sato T, Mizuki N, Shiragami C, Iida T, Khor CC, Wong TY, Yamada R, Honda S, de Jong EK, Hollander AID, Matsuda F, Yamashiro K, Tsujikawa A. Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy. Commun Biol. 2019;2:468.
  2. Misawa N, Tagami M, Kohno T, Honda S. Correlation between visual acuity and human leukocyte antigen DRB1*04 in patients with Vogt-Koyanagi-Harada disease. BMC Ophthalmol. 2019;19:214.
  3. Sakurada Y, Tanaka K, Miki A, Matsumoto H, Kawamura A, Mukai R, Akiyama H, Honda S, Mori R, Iijima H. Clinical characteristics of cuticular drusen in the Japanese population. Jpn J Ophthalmol. 2019;63:448-456.
  4. Nakai S, Matsumiya W, Miki A, Honda S, Nakamura M. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2019;63:389-395.
  5. Hirayama K, Yamamoto M, Kohno T, Teisen-kunde D, Brinkmann R, Miura Y, Honda S. Change in the Thickness of Retinal Layers after Selective Retina Therapy (SRT) in Patients with Central Serous Chorioretinopathy. Osaka City Medical Journal. 2019;65:55-63.
  6. Nakai S, Matsumiya W, Keiko O, Miki A, Nakamura M, Honda S. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2019;63:100-108.
  7. Terasaki H, Shiraki K, Ohji M, Metzig C, Schmelter T, Zeitz O, Sowade O, Kobayashi M, Vitti R, Berliner A, Shiraga F. Efficacy and safety outcomes of intravitreal aflibercept focusing on patients with diabetic macular edema from japan. Retina. 2019;39:938-947.

研究業績　2018年

  1. Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, Yuzawa M. Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study. Clin Ophthalmol. 2018;12:1789-1799.
  2. Miki A, Sakurada Y, Tanaka K, Semba K, Mitamura Y, Yuzawa M, Tajima A, Nakatochi M, Yamamoto K, Matsuo K, Imoto I, Honda S. Genome-Wide Association Study to Identify a New Susceptibility Locus for Central Serous Chorioretinopathy in the Japanese Population. Invest Ophthalmol Vis Sci. 2018;59:5542-5547.

研究業績　2017年以前

  1. Yasui A, Yamamoto M, Hirayama K, Shiraki K, Theisen-Kunde D, Brinkmann R, Miura Y, Kohno T. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255:243-254.
  2. Nakai S, Honda S, Matsumiya W, Miki A, Nakamura M. ARMS2 variants may predict the 3-year outcome of photodynamic therapy for wet age-related macular degeneration. Mol Vis. 2017;23:514-519.
  3. Ikeda N, Ikeda T, Kohno T. Traumatic myopia secondary to ciliary spasm after blunt eye trauma and reconsideration of its pathogenesis. Graefes Arch Clin Exp Ophthalmol. 2016;254:1411-7.
  4. Nagasaki J, Nishimoto M, Nakamae H, Nakane T, Koh H, Yoshimoto K, Shiraki K, Hino M. Optic Neuritis Associated with Myelodysplastic Syndrome Accompanied by Eosinophilic Crisis. Intern Med. 2015;54:2241-4.
  5. Yamaguchi M, Ataka S, Shiraki K. Subretinal fluid drainage via original retinal breaks for rhegmatogenous retinal detachment. Can J Ophthalmol. 2014;49:256-60.
  6. Iwami H, Pruessner J, Shiraki K, Brinkmann R, Miura Y. Protective effect of a laser-induced sub-lethal temperature rise on RPE cells from oxidative stress. Exp Eye Res. 2014;124:37-47.
  7. Matsumiya W, Honda S, Yanagisawa S, Miki A, Nagai T, Tsukahara Y. Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics. 15:833-43, 2014.
  8. Yoshida Y, Kohno T, Yamamoto M, Yoneda T, Iwami H, Shiraki K. Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2013;57:283-93.
  9. Matsuda K, Yokoyama T, Matsumoto H, Yamashita R, Kohno T, Shiraki K. [Relationship between birth month and corneal radius or axial length]. Nippon Ganka Gakkai Zasshi. 2013;117:102-9.
  10. Honda S, Bessho H, Kondo N, Kusuhara S, Tsukahara Y, Negi A. Positive association of CD36 gene variants with the visual outcome of photodynamic therapy in polypoidal choroidal vasculopathy. Mol Vis. 2012;18:2796-804.
  11. Ataka S, Yamaguchi M, Kohno T, Shiraki K. A case of persistent hypotony following 23-gauge vitrectomy. Int Ophthalmol. 2012;32:177-81.
  12. Tano Y, Ohji M; EXTEND-I Study Group. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol. 2011;89:208-17.
  13. Bessho H, Honda S, Kondo N, Negi A. The association of ARMS2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Mol Vis. 17:977-982, 2011.
  14. Iwami H, Kohno T, Yamamoto M, Kaida M, Miki N, Ataka S, Shiraki K. Progression of cataracts following photodynamic therapy combined with intravitreous triamcinolone injection in cases of age-related macular degeneration. Osaka City Med J. 2011;57:49-57.
  15. Yamaguchi M, Yokoyama T, Shiraki K. Surgical procedure for correcting globe dislocation in highly myopic strabismus. Am J Ophthalmol. 2010;149:341-346.e2
  16. Nomura Y, Nakakura S, Moriwaki M, Takahashi Y, Shiraki K. Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma. Clin Ophthalmol. 2010;4:643-7.
  17. Tano Y, Ohji M; EXTEND-I Study Group. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol. 2010;88:309-16.